Vidyashankar Revan, MD
Allergy & Immunology · Wilmington, OHNPI 1194882571
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.4%), food and beverage and education — rather than concentrated in one kind of arrangement. Novartis accounts for 61.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $5,384 and has fallen 83.4% since, to $892 in 2025.
Across 138 payments — averaging $58.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- AstraZeneca$809
- GSK$787
- Sanofi$559
- Regeneron Healthcare Solutions, Inc.$430
- Optinose US, Inc.$157
- plus $392 from 9 others
What the payments were for
- Consulting fees$4,75058%
- Food & beverage$3,34041%
- Education$491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $5,006 |
| AstraZeneca | 23 | $809 |
| GSK | 41 | $787 |
| Sanofi | 27 | $559 |
| Regeneron Healthcare Solutions, Inc. | 17 | $430 |
| Optinose US, Inc. | 5 | $157 |
| Grifols USA, LLC | 1 | $98 |
| Kaleo, Inc. | 3 | $65 |
| Covis Pharma GmbH | 3 | $57 |
| Sanofi-aventis U.S. LLC | 1 | $49 |
| Hikma Pharmaceuticals USA | 3 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Pfizer | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $18 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$234
- DUPIXENT$125
- TEZSPIRE$122
- BREZTRI AEROSPHERE$120
- FASENRA$105
How this compares
$8,139 in reported general payments places this provider in the 70th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 11 | $42,668 |
| Arnuity ElliptaFluticasone Furoate | 82 | $23,997 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $13,106 |
| Fluticasone Propionate HfaFluticasone Propionate | 39 | $8,989 |
| DuleraMometasone/Formoterol | 17 | $8,834 |
| Epinephrine | 47 | $8,343 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,297 |
| Qvar RedihalerBeclomethasone Dipropionate | 23 | $5,137 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 38 | $3,381 |
| Fluticasone Propionate | 206 | $2,514 |
| BreynaBudesonide/Formoterol Fumarate | 17 | $2,418 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 83 | $2,169 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $1,352 |
| Montelukast Sodium | 123 | $1,079 |
| Azelastine Hcl | 48 | $1,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKArnuity Ellipta, Breo Ellipta | $787 | $32,29499 claims |
| AstraZenecaSymbicort | $809 | $13,10626 claims |
| Hikma Pharmaceuticals USAEpinephrine | $46 | $8,34347 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $24 | $5,13723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 128 allergy & immunology providers in Ohio.
Other allergy & immunology in Wilmington
- Justin GreiweCincinnati$1M
- Jonathan BernsteinCincinnati$810K
- Adam UpdegraffToledo$379K
- Syed RehmanToledo$374K
- Gordon MyersCincinnati$346K
- Nancy Wasserbauer KingstonRocky River$256K
- David LangCleveland$251K
- James FernandezCleveland$179K
- Donald McNeilColumbus$136K
- Amber PattersonFindlay$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.